Subtype
Liver Carcinoma
CI-CAN-00001073Explore in graph →
783 active trials14 approved drugs17 evidence items
- NCIt
- C7927
Loading cancer entity…
Loading cancer entity…
Subtype
CI-CAN-00001073Explore in graph →
Clinical trials
3,370 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (387)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT02526043 | Laparoscopic Versus Open Liver Resection for Hepatocellular Carcinoma | unknown | N/A | 180 | Fudan UniversityOTHER | 1 | Aug 18, 2022 | clinicaltrials |
| NCT04782804 | Adjuvant PD-1 Antibody in Combination With Capecitabine for Patients With ICC at High-Risk of Postoperative Recurrence | unknown | Phase 1 / Phase 2 | 30 | Fudan UniversityOTHER | 1 | Aug 18, 2022 | clinicaltrials |
| PD-1 Antibody and Lenvatinib Plus TACE on Downstaging BCLC B/C HCC |
| unknown |
| Early Phase 1 |
| 50 |
| Fudan UniversityOTHER |
| 1 |
| Aug 18, 2022 |
| clinicaltrials |
| NCT05493332 | HAIC Combined With Donafenib Tosilate and Toripalimab for Unresectable HCC | unknown | Phase 2 | 93 | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen UniversityOTHER | 0 | Aug 18, 2022 | clinicaltrials |
| NCT03744624 | Application of 3D Printing in Laparoscopic Surgery of Liver Tumors | unknown | N/A | 85 | Jagiellonian UniversityOTHER | 1 | Aug 15, 2022 | clinicaltrials |
| NCT05059821 | Personalized Cancer Vaccine in Egyptian Cancer Patients(PROVE) | unknown | Phase 1 | 10 | zeinab ahmed yousif hasan ashourOTHER | 1 | Aug 11, 2022 | clinicaltrials |
| NCT05488587 | Serum Levels of Some Trace Elements in Hepatocellular Carcinoma Patients | unknown | — | 100 | Sohag UniversityOTHER | 1 | Aug 9, 2022 | clinicaltrials |
| NCT05491889 | Outcome of Hepatocellular Carcinoma Patients With Portal Vein Thrombosis After Trans-Arterial Chemo Embolization | unknown | — | 30 | Assiut UniversityOTHER | 0 | Aug 8, 2022 | clinicaltrials |
| NCT05290116 | HAIC Combined With Tislelizumab and Apatinib for Unresectable Intrahepatic Cholangiocarcinoma | unknown | Phase 2 | 17 | Yunfei YuanOTHER | 1 | Aug 5, 2022 | clinicaltrials |
| NCT05490147 | Effect of Low Tidal Ventilation on Intraoperative Bleeding in Laparoscopic Major Hepatectomy | unknown | N/A | 58 | Seoul National University HospitalOTHER | 1 | Aug 5, 2022 | clinicaltrials |
| NCT03838796 | Lenvatinib Combined With TACE to Prevent the Recurrence in High-risk Patients With Hepatocellular Carcinoma | unknown | N/A | 297 | Fudan UniversityOTHER | 1 | Aug 2, 2022 | clinicaltrials |
| NCT05472896 | TACE With Dicycloplatin(TP21) in Unresectable HCC | unknown | Phase 3 | 332 | Gao-jun TengOTHER | 1 | Jul 25, 2022 | clinicaltrials |
| NCT05458791 | Intra-arterial Perfusion in Interventional Radiology | unknown | — | 20 | Palo Alto Veterans Institute for ResearchOTHER | 1 | Jul 19, 2022 | clinicaltrials |
| NCT05449860 | Radiofrequency Ablation for Recurrent Hepatocellular Carcinoma With Twin Cooled-wet Electrodes | unknown | N/A | 102 | Seoul National University HospitalOTHER | 1 | Jul 8, 2022 | clinicaltrials |
| NCT04637048 | Observational Study on Patients With Hepatobiliary Tumors | unknown | — | 1,000 | Gang Chen, MDOTHER | 1 | Jun 16, 2022 | clinicaltrials |
| NCT05397860 | Radiofrequency Ablation With Gradual Radiofrequency Energy Increment for Hepatocellular Carcinoma Treatment | unknown | N/A | 120 | Seoul National University HospitalOTHER | 1 | Jun 15, 2022 | clinicaltrials |
| NCT05420922 | Real-world Study of Efficacy and Safety of ICIs and TKIs Therapy for HCC | unknown | — | 2,000 | Tongji HospitalOTHER | 1 | Jun 15, 2022 | clinicaltrials |
| NCT04174781 | Anti-PD-1 Antibody Plus DEB-TACE for BCLC Stage A/B HCC | unknown | Phase 2 | 61 | Zhejiang UniversityOTHER | 1 | Jun 9, 2022 | clinicaltrials |
| NCT05411926 | Effect of PD-1 /PD-L1 Inhibitor Therapy Before Liver Transplantation on Acute Rejection After Liver Transplantation in Patients With Hepatocellular Carcinoma | unknown | — | 30 | Beijing Tsinghua Chang Gung HospitalOTHER | 1 | Jun 9, 2022 | clinicaltrials |
| NCT05002452 | Observational Study of Factors Predicting Therapeutic Effects and Clinical Prognosis After HAIC for Locally Advanced HCC | unknown | — | 150 | Sun Yat-sen UniversityOTHER | 1 | Jun 8, 2022 | clinicaltrials |
| NCT05396937 | Efficacy and Safety of T+A+RAD in HCC | unknown | Phase 2 | 42 | Fudan UniversityOTHER | 1 | May 31, 2022 | clinicaltrials |
| NCT05391867 | Assessment of the Efficacy of Lenvatinib Versus Sorafenib in the Management of Advanced Hepatocellular Carcinoma | unknown | N/A | 70 | Sir Salimullah Medical College Mitford HospitalOTHER_GOV | 1 | May 26, 2022 | clinicaltrials |
| NCT05231382 | Hepatic Arterial Infusion of Raltetrexed With Oxaliplatin(SALOX) Versus FOLFOX in Advanced Hepatocellular Carcinoma | unknown | Phase 3 | 426 | Sun Yat-sen UniversityOTHER | 1 | May 24, 2022 | clinicaltrials |
| NCT05220020 | TACE Combined With Lenvatinib Versus TACE Sequential Lenvatinib in the Treatment of Intermediate/Advanced Liver Cancer | unknown | Phase 3 | 299 | Sun Yat-sen UniversityOTHER | 1 | May 19, 2022 | clinicaltrials |
| NCT05383066 | Anti-angiogenesis Combined With PD-1/PD-L1 Therapy in Patients With Advanced Liver Cancer | unknown | — | 490 | Peking University First HospitalOTHER | 0 | May 19, 2022 | clinicaltrials |
| NCT05376943 | Possible Differences in HCC Course Depending on DAA Treatment | unknown | — | 100 | Medical University of WarsawOTHER | 1 | May 17, 2022 | clinicaltrials |
| NCT05339321 | Autologous HBV-specific T Cell Receptor Engineered T Cells (TCR-T) in Patients With HBV-related Advanced HCC | unknown | Phase 1 | 36 | Peking Union Medical College HospitalOTHER | 1 | May 10, 2022 | clinicaltrials |
| NCT05363722 | A Clinical Study to Observe the Effectiveness and Safety of IBI310, Bevacizumab Combined With Sintilimab in the Treatment of Advanced Hepatocellular Carcinoma | unknown | Phase 1 | 80 | Shanghai Zhongshan HospitalOTHER | 0 | May 6, 2022 | clinicaltrials |
| NCT05214339 | A Trial of Hepatic Arterial Infusion Combined With Bevacizumab and Sintilimab for Unresectable A-staged Hepatocellular Carcinoma in BCLC Classification (D-TRIPLET) | unknown | Phase 2 | 30 | Sun Yat-sen UniversityOTHER | 1 | May 5, 2022 | clinicaltrials |
| NCT05111366 | TQB2450 Plus Anlotinib as Adjuvant Therapy in HCC Patients at High Risk of Recurrence After Resection(ALTER-H006) | unknown | Phase 2 | 37 | Xianhai MaoOTHER | 1 | May 4, 2022 | clinicaltrials |
| NCT04564313 | Safety and Efficacy of Camrelizumab (Anti-PD-1 Antibody) in Recurrent HCC After Liver Transplantation | unknown | Phase 1 | 20 | Third Affiliated Hospital, Sun Yat-Sen UniversityOTHER | 1 | May 3, 2022 | clinicaltrials |
| NCT05290220 | HLX07 Combination Therapy or Motherapy in Patient With Advanced Hepatocellular Carcinoma | unknown | Phase 2 | 60 | Shanghai Henlius BiotechINDUSTRY | 0 | May 3, 2022 | clinicaltrials |
| NCT02562963 | Clinical Efficacy and Safety of NKT Cell Infusion in Patients With Advanced Solid Tumor | unknown | Phase 1 / Phase 2 | 120 | Minghui ZhangOTHER | 1 | May 2, 2022 | clinicaltrials |
| NCT04487704 | Camrelizumab Utilization on Patients With Advanced Liver Cancer | unknown | N/A | 1,000 | First Affiliated Hospital Xi'an Jiaotong UniversityOTHER | 1 | Apr 29, 2022 | clinicaltrials |
| NCT05353894 | Effect of Food and Formulation on the Pharmacokinetics, Safety, and Tolerability of GNS561 After One Single Dose (50 and 200mg) in Healthy Volunteers | unknown | Phase 1 | 27 | Genoscience PharmaINDUSTRY | 1 | Apr 29, 2022 | clinicaltrials |
| NCT02794337 | TACE vs TACE+SBRT for Unresectable Hepatocellular Cancer(TACE-SBRT) | unknown | Phase 2 / Phase 3 | 67 | Tata Memorial HospitalOTHER_GOV | 1 | Apr 27, 2022 | clinicaltrials |
| NCT05339581 | IMRT Plus PD-1 Blockade and Lenvatinib for HCC With PVTT (Vp3) Before Liver Transplantation(iPLENTY-pvtt) | unknown | N/A | 78 | RenJi HospitalOTHER | 1 | Apr 27, 2022 | clinicaltrials |
| NCT05171439 | Surufatinib in Advanced Hepatocellular Carcinoma Based on Single-cell Sequencing of Tumor Samples | unknown | Phase 2 | 6 | The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical SchoolOTHER | 1 | Apr 14, 2022 | clinicaltrials |
| NCT05327907 | Establishment of Scoring Model for Early and Differential Diagnosis of Intrahepatic Cholangiocarcinoma | unknown | — | 300 | Qilu Hospital of Shandong UniversityOTHER | 1 | Apr 14, 2022 | clinicaltrials |
| NCT05024539 | Real-World Effectiveness of Regorafenib in the Treatment of Patients With Hepatocellular Carcinoma | unknown | — | 300 | Shujun YangOTHER_GOV | 1 | Apr 5, 2022 | clinicaltrials |
| NCT05311319 | HAIC Combined With Anlotinib and TQB2450 as Adjuvant Therapy in HCC Patients With High Risk of Recurrence After Resection | unknown | Phase 2 | 70 | Fudan UniversityOTHER | 1 | Apr 5, 2022 | clinicaltrials |
| NCT04943679 | Anti-PD-1/PD-L1 Antibodies Plus Pegylated Interferon Alfa-2b Treatment in Patients With Advanced-Stage HCC | unknown | — | 15 | Shanghai Zhongshan HospitalOTHER | 1 | Mar 31, 2022 | clinicaltrials |
| NCT05200221 | A Single Center Real-world Study of Donafenib in the Treatment of Hepatocellular Carcinoma in Routine Clinical Practice | unknown | — | 300 | Shanghai Zhongshan HospitalOTHER | 1 | Mar 31, 2022 | clinicaltrials |
| NCT03086993 | Percutaneous Hepatic Perfusion vs. Cisplatin/Gemcitabine in Patients With Intrahepatic Cholangiocarcinoma | unknown | Phase 2 / Phase 3 | 295 | Delcath Systems Inc.INDUSTRY | 1 | Mar 24, 2022 | clinicaltrials |
| NCT05205629 | A Real-world Study of Donafenib Combined With TACE-based Treatment in Patients With Unresectable HCC | unknown | — | 150 | Shanghai Zhongshan HospitalOTHER | 1 | Mar 23, 2022 | clinicaltrials |
| NCT05286099 | The Surveillance of Hepatocellular Carcinoma | unknown | — | 100 | Chinese PLA General HospitalOTHER | 1 | Mar 18, 2022 | clinicaltrials |
| NCT05281926 | A Phase I, Open-label Study to Assess the Safety and Efficacy of Poly-ICLC Plus Nivolumab in Unresectable Hepatocellular Carcinoma Patients | unknown | Phase 1 | 10 | National Taiwan University HospitalOTHER | 1 | Mar 16, 2022 | clinicaltrials |
| NCT05282433 | Surufatinib Alone or Combined With Anti-PD-1 mAb in the Treatment of Advanced Hepatocellular Carcinoma | unknown | Phase 2 | 45 | Zhongnan HospitalOTHER | 1 | Mar 16, 2022 | clinicaltrials |
| NCT05277675 | Radiofrequency Ablation Plus Systematic Neoadjuvant Therapy for Recurrent Hepatocellular Carcinoma (RANT Study)(RANT) | unknown | N/A | 160 | Southwest Hospital, ChinaOTHER | 1 | Mar 14, 2022 | clinicaltrials |
Data updated 23 days agoSource updated Aug 18, 2022source: clinicaltrials